BRINGING IMPACT IN THREE THERAPEUTIC AREAS
We are laser-focused on developing innovative treatments within our three therapeutic areas: oncology, neuroscience and rare disease. We believe that concentrating on diseases and disorders within these areas, we can make a positive impact on the lives of patients and their families.
Our products are the result of decades of experience and years of research and development. We are proud of the portfolio of medicines we have brought to market, and we are determined in our efforts to find the next wave of treatments for patients.
Product names, availability, and indicated uses may vary by country. Not all products are available in all countries. Please consult your local Ipsen website for more information on the products available in your region. Patients should always ask a healthcare professional for advice.
Our products
Filter
Disease Areas
Showing: 1 – 05 of 11 Product
Bylvay® (odevixibat)
Bylvay is a non-systemic ileal bile acid transport inhibitor (IBATi), that treats Progressive Familial Intrahepatic Cholestasis (PFIC) and other rare cholestatic diseases in children
Cabometyx® (cabozantinib)
A tyrosine kinase inhibitor (TKI) used in the treatment of advanced kidney cancer (advanced renal cell carcinoma – aRCC) as monotherapy or in combination with nivolumab. It is also indicated in adults living with liver cancer (hepatocellular carcinoma) previously treated with the medicine sorafenib. In the E.U., it is also indicated for the treatment of adults with locally advanced or metastatic differentiated thyroid carcinoma (DTC), who are refractory or not eligible to radioactive iodine and who have progressed after prior systemic therapy.
Cometriq® (cabozantinib)
A tyrosine kinase inhibitor (TKI) used to treat people with progressive, unresectable or locally advanced medullary thyroid cancer (MTC) or MTC that has spread to other parts of the body (metastatic MTC).
Decapeptyl® (triptorelin pamoate or acetate)
An analog of the natural gonadotropin-releasing hormone (GnRH), halting the production of sexual hormones. It is approved for the treatment of high-risk localized, locally advanced or metastatic prostate cancer, endometriosis, uterine fibroids and central precocious puberty (CPP). It is also approved as an adjuvant treatment in combination with tamoxifen or an aromatase inhibitor for women at high risk of recurrence of endocrine-responsive early-stage breast cancer. It is also used to induce ovulation for in vitro fertilization.
Dysport® (abobotulinumtoxinA)
An acetylcholine release inhibitor and a neuromuscular blocking agent, Dysport contains a toxin produced by the bacterium Clostridium botulinum indicated for symptomatic treatment of focal spasticity of the upper and lower limbs in adults and children over two years old.
It is also indicated for adults for symptomatic treatment of:
- Spasmodic torticollis (cervical dystonia)
- Blepharospasm
- Hemifacial spasm
- Severe primary hyperhidrosis of the axillae
Also used for the temporary improvement in the appearance of moderate to severe glabellar and lateral canthal lines associated with procerus and corrugator muscle activity in adults under 65.
Request medical information / report adverse event or product complaint
To request medical information on Ipsen’s products, report an adverse event or report a complaint, please visit: Ipsen Medical Information or email us at globalmedinfo@ipsen.com
Adverse event reactions can also be reported directly to Ipsen’s local safety team using the contact details provided in the contact us pages
Related contact
-
Product & medical information
-
